ASX:COHMedical Equipment
Cochlear (ASX:COH) Could Be 76% Overvalued After Osia 3 FDA Clearance
Cochlear (ASX:COH) is back in the spotlight after receiving FDA clearance for its Osia 3 Sound Processor, a new fully rechargeable bone conduction device that supports the company’s upgrade driven hearing implant model.
See our latest analysis for Cochlear.
Despite the positive headlines around Osia 3, Cochlear’s recent share price return has been mixed. A 30 day gain of about 15.4% contrasts with a year to date share price decline of around 52.8% and a 1 year total shareholder return that is...